Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 11/20 | 0.50 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.43 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27679590 | 0.85 | KCNJ1 (0.49) | LTA4HKCNJ1KCNH2HPGDSCHRNA7 | |
| SCHEMBL722557 | 0.83 | LTA4H (0.64) | LTA4HKCNJ1KCNH2HPGDSCHRNA7 | |
| SCHEMBL9094687 | 0.82 | KCNJ1 (0.47) | LTA4HKCNJ1KCNH2HPGDSCHRNA7 | |
| Ammonia Solution, Strong SCHEMBL28198912 | 0.82 | LTA4H (0.42) | LTA4HKCNJ1KCNH2HPGDSCHRNA7 | |
| SCHEMBL28257875 | 0.81 | LTA4H (0.62) | LTA4HKCNJ1KCNH2HPGDSCHRNA7 | |
| SCHEMBL28362996 | 0.81 | LTA4H (0.62) | LTA4HKCNJ1KCNH2HPGDSCHRNA7 | |
| SCHEMBL28320605 | 0.81 | LTA4H (0.62) | LTA4HKCNJ1KCNH2HPGDSCHRNA7 | |
| SCHEMBL8239613 | 0.81 | LTA4H (0.50) | LTA4HKCNJ1KCNH2HPGDSCHRNA7 | |
| SCHEMBL3373791 | 0.81 | LTA4H (0.50) | LTA4HKCNJ1KCNH2HPGDSCHRNA7 | |
| SCHEMBL10366022 | 0.81 | LTA4H (0.50) | LTA4HKCNJ1KCNH2HPGDSCHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12365672-B2 | Compounds and their use for the treatment of alpha1-antitrypsin deficiency | CENTESSA PHARMACEUTICALS (UK) LIMITED (GB) | 2025-07-22 | — | — | US | disclosed |
| EP-4073068-B1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY | CENTESSA PHARMACEUTICALS UK LTD (GB) | 2024-04-24 | — | — | EP | disclosed |
| US-20230093755-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY | OXFORD FINANCE LLC | 2023-03-23 | — | — | US | disclosed |
| WO-2022263829-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY | Z Factor Limited (GB) | 2022-12-22 | — | — | WO | disclosed |
| EP-4073068-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF a1-ANTITRYPSIN DEFICIENCY | Z Factor Limited (GB) | 2022-10-19 | — | — | EP | disclosed |
| WO-2021116710-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY | Z Factor Limited (GB) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021116710-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY | Z Factor Limited (GB) | 2021-06-17 | — | — | WO | disclosed |
| EP-2408756-B1 | ALPHA-(N-BENZENESULFONAMIDO)CYCLOALKYL DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-2408756-A1 | ALPHA-(N-BENZENESULFONAMIDO)CYCLOALKYL DERIVATIVES | Bristol-Myers Squibb Company (US) | 2012-01-25 | — | — | EP | disclosed |
| US-7977362-B2 | Alpha-(N-benzenesulfonamido)cycloalkyl derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-12 | — | — | US | disclosed |
| EP-2278878-A1 | 2-ARYL GLYCINAMIDE DERIVATIVES | Bristol-Myers Squibb Company (US) | 2011-02-02 | — | — | EP | disclosed |
| WO-2010108067-A1 | ALPHA-(N-BENZENESULFONAMIDO)CYCLOALKYL DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-23 | — | — | WO | disclosed |
| US-20100240708-A1 | Alpha-(N-Benzenesulfonamido)Cycloalkyl Derivatives | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-23 | — | — | US | disclosed |
| WO-2009137657-A1 | 2-ARYL GLYCINAMIDE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-12 | — | — | WO | disclosed |
| US-7345095-B2 | Sulfonamide compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070129349-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC | 2007-06-07 | — | — | US | disclosed |
| EP-1747195-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Incorporated (US) | 2007-01-31 | — | — | EP | disclosed |
| US-7163942-B2 | Sulfonamide compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2007-01-16 | — | — | US | disclosed |
| WO-2005095334-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20050222254-A1 | Sulfonamide compounds for the treatment of neurodegenerative disorders | PFIZER INC | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240708-A1 | Alpha-(N-Benzenesulfonamido)Cycloalkyl Derivatives | BACE1, BACE2, APP | LTA4H 838/4885KCNJ1 3106/4885KCNH2 2774/4885 |
| US-20230093755-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY | SERPINA2, SERPINC1, SERPINB1 | LTA4H 371/4885KCNJ1 3360/4885KCNH2 4522/4885 |
| US-20070129349-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PSEN1, APP, PSEN2 | LTA4H 3201/4885KCNJ1 989/4885KCNH2 1643/4885 |
| US-20050222254-A1 | Sulfonamide compounds for the treatment of neurodegenerative disorders | PSEN1, APP, PSEN2 | LTA4H 3002/4885KCNJ1 949/4885KCNH2 1511/4885 |
| US-12365672-B2 | Compounds and their use for the treatment of alpha1-antitrypsin deficiency | SERPINA2, SERPINC1, SERPINB1 | LTA4H 371/4885KCNJ1 3360/4885KCNH2 4522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.